Compare AMETEK, Inc. (AME) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Citius Pharmaceuticals Inc — how do they compare? AMETEK, Inc. trades at $231.8 (market cap $53.63B), while Citius Pharmaceuticals Inc trades at $0.58 (market cap $16.00M). The key difference: AMETEK, Inc. is far larger — about 3351.9× Citius Pharmaceuticals Inc's market cap, and AMETEK, Inc. pays a 0.58% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AME | CTXR | |
|---|---|---|
Market Cap | $53.63B | $16.00M |
Sector | Industrials | Health |
52-Week High | $241.94 | $1.82 |
52-Week Low | $176.44 | $0.53 |
Enterprise Value | $55.33B | $12.21M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
CTXR trades at $0.5827, up 3.81% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported a net loss of $37.43M in 2025 with a -823.34% net margin, though revenue reached $5.6M in H1 2026 from LYMPHIR commercialization. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO 2026.
Outlook remains speculative with high cash burn offset by financing; analyst consensus is 83% buy but financial sustainability depends on successful drug adoption. Key risks include clinical trial outcomes, dilution from recent $5M offering, and achieving profitability amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
